Neuroprotective Action of N-acetyl Serotonin in Oxidative Stress-induced Apoptosis Through the Activation of Both TrkB/CREB/BDNF Pathway and Akt/Nrf2/Antioxidant Enzyme in Neuronal Cells
Overview
Cell Biology
Endocrinology
Affiliations
N-acetyl serotonin (NAS) as a melatonin precursor has neuroprotective actions. Nonetheless, it is not clarified how NAS protects neuronal cells against oxidative stress. Recently, we have reported that N-palmitoyl serotonins possessed properties of antioxidants and neuroprotection. Based on those, we hypothesized that NAS, a N-acyl serotonin, may have similar actions in oxidative stress-induced neuronal cells, and examined the effects of NAS based on in vitro and in vivo tests. NAS dose-dependently inhibited oxidative stress-induced cell death in HT-22 cells. Moreover, NAS suppressed glutamate-induced apoptosis by suppressing expression of AIF, Bax, calpain, cytochrome c and cleaved caspase-3, whereas it enhanced expression of Bcl-2. Additionally, NAS improved phosphorylation of tropomyosin-related kinase receptor B (TrkB) and cAMP response element-binding protein (CREB) as well as expression of brain-derived neurotrophic factor (BDNF), whereas the inclusion of each inhibitor of JNK, p38 or Akt neutralized the neuroprotective effect of NAS, but not that of ERK. Meanwhile, NAS dose-dependently reduced the level of reactive oxygen species, and enhanced the level of glutathione in glutamate-treated HT-22 cells. Moreover, NAS significantly increased expression of heme oxygenase-1, NAD(P)H quinine oxidoreductase-1 and glutamate-cysteine ligase catalytic subunit as well as nuclear translocation of NF-E2-related factor-2. Separately, NAS at 30mg/kg suppressed scopolamine-induced memory impairment and cell death in CA1 and CA3 regions in mice. In conclusion, NAS shows actions of antioxidant and anti-apoptosis by activating TrkB/CREB/BDNF pathway and expression of antioxidant enzymes in oxidative stress-induced neurotoxicity. Therefore, such effects of NAS may provide the information for the application of NAS against neurodegenerative diseases.
Lu J, Zhou Q, Zhu D, Song H, Xie G, Zhao X Acta Pharm Sin B. 2025; 15(1):371-391.
PMID: 40041886 PMC: 11873626. DOI: 10.1016/j.apsb.2024.11.010.
Kadyan P, Singh L Mol Neurobiol. 2025; .
PMID: 40038194 DOI: 10.1007/s12035-025-04808-6.
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.
Xing C, Chen H, Bi W, Lei T, Hang Z, Du H Int J Mol Sci. 2025; 25(24.
PMID: 39769209 PMC: 11679250. DOI: 10.3390/ijms252413446.
Nguyen C, Yoo J, Jeong S, Ha H, Yang J, Lee G Chin Med. 2024; 19(1):166.
PMID: 39605070 PMC: 11603938. DOI: 10.1186/s13020-024-01020-x.
Jeong Y, Li W, Yang H, Kim S, Choi H, Choi J Antioxidants (Basel). 2024; 13(11).
PMID: 39594488 PMC: 11591166. DOI: 10.3390/antiox13111346.